Billie Sue Mayo
Primary Care · Nampa, IDNPI 1396245742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 33.2% of the total. Reporting peaked in 2022 at $883 and has fallen 97.5% since, to $22 in 2024.
Across 131 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$763
- Novo Nordisk$214
- Idorsia Pharmaceuticals US Inc$187
- Takeda Pharmaceuticals U.S.A., Inc.$164
- Lilly USA, LLC$157
- Boehringer Ingelheim$140
- plus $673 from 18 others
What the payments were for
- Food & beverage$2,28699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $763 |
| Novo Nordisk | 6 | $214 |
| Idorsia Pharmaceuticals US Inc | 4 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $164 |
| Lilly USA, LLC | 8 | $157 |
| Boehringer Ingelheim | 7 | $140 |
| AstraZeneca | 9 | $129 |
| Corium, LLC | 4 | $98 |
| Johnson & Johnson | 3 | $93 |
| Janssen Scientific Affairs, LLC | 1 | $57 |
| Pfizer | 2 | $38 |
| Lundbeck LLC | 2 | $37 |
| Amgen | 1 | $33 |
| Alkermes, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Novartis | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Organon | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,298 in reported general payments places this provider in the 85th percentile of 48 primary care providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 24 | $34,878 |
| VraylarCariprazine Hcl | 21 | $34,112 |
| MounjaroTirzepatide | 19 | $25,275 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $24,884 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $16,393 |
| Gabapentin | 74 | $2,420 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $2,036 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,543 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,513 |
| Atorvastatin Calcium | 91 | $1,034 |
| Minocycline Hcl | 13 | $978 |
| Omeprazole | 65 | $976 |
| Rosuvastatin Calcium | 22 | $897 |
| Fentanyl | 12 | $798 |
| Montelukast Sodium | 58 | $790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $157 | $60,51956 claims |
| AbbVieVraylar | $763 | $34,11221 claims |
| AstraZenecaBreztri Aerosphere | $129 | $16,39327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 primary care providers in Idaho.
Other primary care in Nampa
- Brianna CracoliceNampa$2K
- Amanda BledsoeNampa$1K
- Lauren ParkerNampa$673
- Christina CyrwayNampa$638
- Tina Bossolono-WilliamsNampa$434
- Christine CooperNampa$101
- Bradley RadfordIdaho Falls$8K
- Kathryn NielsenIdaho Falls$5K
- Jessica ButterfieldBoise$5K
- Teirza BristowKellogg$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.